Literature DB >> 21975820

Inhibitory effects of sepiapterin on vascular endothelial growth factor-A-induced proliferation and adhesion in human umbilical vein endothelial cells.

Soo Hyeon Kim1, Young-Rak Cho, Myoung-Dong Kim, Hyun Ju Kim, Shin Wook Choi, Dong-Wan Seo.   

Abstract

Tetrahydrobiopterin (BH(4)) has been known to be an essential cofactor for the activities of nitric oxide (NO) synthase and aromatic amino acid hydroxylases, which are involved in physiological and pathological processes. In the present study, we report that sepiapterin, the more stable form of BH4 precursor, modulates vascular endothelial growth factor-A (VEGF-A)-induced cell proliferation and adhesion in human umbilical vein endothelial cells (HUVECs). The antiproliferative activity of sepiapterin in VEGF-A-treated HUVECs is associated with inhibition of the expression of cyclin-dependent kinases (Cdks) such as Cdk4 and Cdk2. Pretreatment with NO synthase inhibitor does not abrogate the ability of sepiapterin to inhibit VEGF-A-induced cell proliferation and adhesion, indicating that the suppressive effects of sepiapterin on VEGF-Ainduced responses are mediated by NO-independent mechanism. Finally, we show that sepiapterin modulates VEGF-A-induced cell proliferation and adhesion through down-regulation of VEGF receptor-2 downstream signaling pathways. Taken together, these findings represent a novel function of sepiapterin in the regulation of angiogenesis, supporting further development and evaluation of sepiapterin as an antiangiogenic agent.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21975820     DOI: 10.1007/s12272-011-0920-7

Source DB:  PubMed          Journal:  Arch Pharm Res        ISSN: 0253-6269            Impact factor:   4.946


  1 in total

1.  The role of KDR in intrauterine adhesions may involve the TGF-β1/Smads signaling pathway.

Authors:  Jian Xia Chen; Xi Juan Yi; Pei Ling Gu; Shan Xia Gao
Journal:  Braz J Med Biol Res       Date:  2019-10-07       Impact factor: 2.590

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.